APPENDIX 2 (as supplied by the authors): Findings by therapeutic category

Table B1: Level and drivers of differences in estimated 2015 expenditure per capita in each country compared to the other nine comparator countries combined, hypertension treatments

to the other		ματατύτ το	untiles CC	ilibilieu,	пурепсен	אטוו נול	aunent	•		
	Mixed		Hater- ·					ludinana - l !	ial imanus	
	financing			public fina	ncing		·	iniversal soci	ial insurance fin	ancing
	Canada	Australia	New Zealand	Norway	Sweden	UK	France	Germany	Netherlands	Switzerland
Domestic										
expenditure	\$37.9	\$20.4	\$7.2	\$14.7	\$11.6	\$16.2	\$31.0	\$27.5	\$11.9	\$44.9
Comparator										
expenditure	\$23.6	\$25.6	\$25.5	\$25.4	\$25.6	\$27.5	\$23.6	\$24.4	\$25.9	\$24.7
Total										
difference										
in										
expenditure										
per capita	61%	-20%	-72%	-42%	-55%	-41%	31%	13%	-54%	82%
Domestic										
days per										
capita	103	86	104	91	124	113	106	158	112	91
Comparator										
days per										
capita	121	122	119	120	119	121	123	106	120	120
Difference										
in volume of										
therapy	-15%	-30%	-13%	-24%	4%	-7%	-13%	50%	-6%	-24%
Difference										
in cost per										
day of										
therapy	75%	9%	-59%	-18%	-59%	-34%	44%	-37%	-48%	106%
Difference										
in										
expenditure										
per capita										
resulting										
from										
differences										
in drivers of										
cost per day										
of therapy										
Broad mix of										
therapies	-1%	8%	-14%	4%	-17%	-20%	12%	5%	-10%	13%
Narrow mix	_,*		,		,,		,3			_3,0
of therapies	-2%	4%	-8%	-11%	-27%	-18%	23%	-21%	-1%	26%
Choice									,-	3,1
Effects -										
subtotal	-3%	12%	-22%	-7%	-43%	-38%	34%	-16%	-11%	40%
Generic use	1%	10%	-3%	8%	3%	-5%	4%	-9%	-12%	14%
Prices	78%	-13%	-34%	-19%	-18%	8%	6%	-12%	-25%	52%
Price Effects	- / -	-,-	- /-	- / -				,-	5,1	32,1
- subtotal	79%	-3%	-37%	-11%	-16%	4%	10%	-21%	-37%	66%
	1		1	1					1	

Table B2: Level and drivers of differences in estimated 2015 expenditure per capita in each country compared to the other nine comparator countries combined, pain medications

to the other		parator co	untines co	Jilibilieu,	pain mec	ilcation	ა 						
	Mixed	Habanalaul P. C.						Habitania la stal ti					
	financing	Universal public financing						Universal social insurance financing					
	Canada	Australia	New Zealand	Norway	Sweden	UK	France	Germany	Netherlands	Switzerland			
Domestic													
expenditure	\$30.1	\$22.3	\$6.7	\$18.1	\$18.9	\$20.0	\$18.0	\$31.1	\$11.5	\$35.0			
Comparator													
expenditure	\$22.6	\$23.5	\$23.7	\$23.5	\$23.5	\$24.3	\$24.8	\$20.8	\$24.1	\$23.1			
Total													
difference													
in													
expenditure													
per capita	33%	-5%	-72%	-23%	-20%	-18%	-28%	50%	-52%	51%			
Domestic													
days per													
capita	20	21	13	14	14	15	17	20	10	17			
Comparator													
days per													
capita	17	17	18	18	18	18	18	17	18	18			
Difference													
in volume of						_	_						
therapy	18%	25%	-24%	-19%	-19%	-17%	-5%	21%	-42%	-3%			
Difference													
in cost per													
day of	460/	200/	400/	-an/	20/	40/	220/	200/	440/	= 40/			
therapy	16%	-30%	-48%	-4%	0%	-1%	-23%	29%	-11%	54%			
Difference													
in													
expenditure													
per capita													
resulting													
from													
differences													
in drivers of													
cost per day													
of therapy													
Broad mix of	201	001	601	001	2221	22/	200/	4001	661	451			
therapies	2%	8%	-6%	0%	-23%	-9%	-38%	19%	-6%	1%			
Narrow mix	201	301	240/	240/	400/	F0/	470/	3.00/	301	4.40/			
of therapies	-2%	2%	-21%	-21%	18%	-5%	17%	-26%	2%	14%			
Choice Effects -													
	00/	00/	369/	310/	40/	1.40/	310/	70/	40/	160/			
subtotal	0%	9%	-26%	-21%	-4%	-14%	-21%	-7%	-4%	16%			
Generic use	-6%	2%	-7%	20%	4%	5%	4%	-4%	-1%	7%			
Prices	22%	-41%	-15%	-3%	0%	8%	-5%	39%	-6%	31%			
Price Effects	4651	2021	2451	4701	45.	4001	201	2001		2001			
- subtotal	16%	-39%	-21%	17%	4%	13%	-2%	36%	-7%	38%			

Table B3: Level and drivers of differences in estimated 2015 expenditure per capita in each country compared to the other nine comparator countries combined, lipid lowering treatments

to the other	Mixed	parator co	untiles co	Jilibilicu,	iipia iowe	ziiig ti		<u> </u>				
	financing	Universal public financing					u	Iniversal soci	ial insurance fin	ancing		
	maneng		New	- pasie ilia			Universal social insurance financing					
	Canada	Australia	Zealand	Norway	Sweden	UK	France	Germany	Netherlands	Switzerland		
Domestic												
expenditure	\$20.8	\$18.7	\$3.2	\$7.4	\$5.6	\$12.4	\$18.7	\$6.7	\$12.2	\$28.0		
Comparator										_		
expenditure	\$12.8	\$13.3	\$13.8	\$13.8	\$13.9	\$14.0	\$12.3	\$16.1	\$13.8	\$13.3		
Total												
difference												
in												
expenditure	630/	440/	770/	470/	C00/	110/	F30/	F.00/	440/	4440/		
per capita	63%	41%	-77%	-47%	-60%	-11%	52%	-58%	-11%	111%		
Domestic												
days per	42	26	20	25	24	42	27	20	20	20		
capita	42	36	39	35	31	43	37	30	39	28		
Comparator												
days per	36	26	26	26	27	25	26	20	26	27		
capita Difference	30	36	36	36	37	35	36	39	36	37		
in volume of												
therapy	16%	-1%	6%	-4%	-16%	22%	2%	-23%	7%	-24%		
Difference	10/8	-1/6	078	-4/0	-10/6	22/0	2/0	-23/6	170	-24/0		
in cost per												
day of												
therapy	47%	42%	-83%	-42%	-44%	-33%	50%	-35%	-19%	134%		
шегеру	,,	,	00,0	1275	,.	3075	5676	00/0	2070	20 1,70		
Difference												
in												
expenditure												
per capita												
resulting												
from												
differences												
in drivers of												
cost per day												
of therapy												
Broad mix of	450/	4.40/	60/	40/	00/	4.60/	450/	5 0/	40/	00/		
therapies	-15%	14%	-6%	-4%	-8%	-16%	15%	5%	-1%	8%		
Narrow mix	460/	270/	200/	200/	260/	420/	200/	420/	420/	470/		
of therapies	46%	37%	-20%	-26%	-26%	-42%	26%	-43%	-13%	17%		
Choice												
Effects -	210/	E00/	360/	210/	250/	E00/	400/	200/	1 /10/	25%		
subtotal	31%	50%	-26%	-31%	-35%	-58%	40%	-39%	-14%			
Generic use	-44%	12%	-4%	22%	4%	22%	14%	2%	10%	10%		
Prices Fff at a	59%	-20%	-53%	-34%	-14%	2%	-5%	1%	-15%	99%		
Price Effects	450/	001	F 70/	430/	400/	350/	400/	301	F0/	4400/		
- subtotal	15%	-8%	-57%	-12%	-10%	25%	10%	3%	-5%	110%		

Table B4: Level and drivers of differences in estimated 2015 expenditure per capita in each country compared to the other nine comparator countries combined, non-insulin diabetes treatments

to the other	Mixed	parator co	untiles co	Jilibilicu,	11011 11134	iii diab		itilicitis				
	financing	Universal public financing					u	Iniversal soci	ial insurance fin	ancing		
			New									
	Canada	Australia	Zealand	Norway	Sweden	UK	France	Germany	Netherlands	Switzerland		
Domestic												
expenditure	\$21.4	\$7.9	\$0.7	\$8.1	\$6.9	\$13.2	\$14.6	\$13.9	\$4.3	\$16.3		
Comparator												
expenditure	\$12.4	\$13.8	\$13.6	\$13.5	\$13.6	\$13.4	\$13.0	\$13.2	\$13.9	\$13.3		
Total												
difference												
in												
expenditure 	== 0./	400/	0=0/	400/	400/	40/	400/	60/	500/	220		
per capita	73%	-43%	-95%	-40%	-49%	-1%	12%	6%	-69%	23%		
Domestic												
days per												
capita	26	16	15	13	16	20	21	20	20	14		
Comparator												
days per			•	••	•	•	•	•				
capita	19	20	20	20	20	20	20	20	20	20		
Difference in volume of												
	34%	100/	350/	220/	100/	10/	4%	20/	00/	200		
therapy Difference	34%	-19%	-25%	-33%	-18%	1%	4%	-3%	0%	-29%		
in cost per												
day of												
therapy	39%	-24%	-70%	-7%	-31%	-2%	8%	9%	-69%	52%		
шегару	33/6	-24/0	-70/8	-7/0	-31/6	-2/0	0/0	3/0	-09/6	32/0		
Difference												
in												
expenditure												
per capita												
resulting												
from												
differences												
in drivers of												
cost per day												
of therapy												
Broad mix of												
therapies	-1%	-1%	-7%	-1%	-1%	2%	0%	-1%	-2%	-1%		
Narrow mix												
of therapies	-14%	-13%	-43%	9%	-20%	-22%	9%	23%	-37%	29%		
Choice												
Effects -												
subtotal	-15%	-14%	-51%	8%	-21%	-20%	9%	22%	-39%	28%		
Generic use	-2%	1%	-3%	1%	-1%	2%	0%	9%	-2%	3%		
Prices	56%	-12%	-17%	-16%	-9%	17%	-1%	-22%	-28%	20%		
Price Effects												
- subtotal	54%	-10%	-19%	-15%	-10%	18%	-1%	-13%	-30%	24%		

Table B5: Level and drivers of differences in estimated 2015 expenditure per capita in each country compared to the other nine comparator countries combined, gastrointestinal preparations

to the other	Mixed	parator co	diffico co	Jilibilica,	Bastronic								
	financing	Universal public financing						Universal social insurance financing					
			New										
	Canada	Australia	Zealand	Norway	Sweden	UK	France	Germany	Netherlands	Switzerland			
Domestic													
expenditure	\$22.7	\$12.6	\$2.4	\$5.7	\$5.0	\$7.3	\$15.0	\$8.6	\$4.2	\$23.0			
Comparator													
expenditure	\$10.0	\$11.4	\$11.6	\$11.6	\$11.7	\$12.5	\$10.5	\$12.5	\$11.9	\$11.2			
Total													
difference													
in													
expenditure							/						
per capita	127%	11%	-79%	-51%	-57%	-42%	42%	-31%	-65%	106%			
Domestic													
days per													
capita	33	31	30	23	26	41	37	32	39	30			
Comparator													
days per	2-	25	25	25	25	22	2.4	26	2.4	25			
capita	35	35	35	35	35	33	34	36	34	35			
Difference in volume of													
	F0/	120/	4.40/	350/	350/	220/	70/	4.20/	130/	130/			
therapy	-5%	-12%	-14%	-35%	-25%	23%	7%	-12%	13%	-13%			
Difference in cost per													
day of													
therapy	131%	23%	-66%	-16%	-32%	-64%	35%	-20%	-77%	119%			
шегару	131/6	23/6	-00/6	-10/6	-32/6	-04/6	33/6	-20/6	-77/6	113/0			
Difference													
in													
expenditure													
per capita													
resulting													
from													
differences													
in drivers of													
cost per day													
of therapy													
Broad mix of							,						
therapies	54%	19%	-13%	-14%	-7%	-19%	45%	-47%	-20%	22%			
Narrow mix	-001						2.27	222					
of therapies	-50%	4%	-14%	13%	-10%	-7%	-21%	39%	-11%	-19%			
Choice													
Effects -	20/	220/	300/	10/	160/	269/	220/	00/	300/	30/			
subtotal	3%	22%	-28%	-1%	-16%	-26%	23%	-9%	-30%	3%			
Generic use	-5%	21%	-4%	14%	1%	-17%	4%	-8%	0%	16%			
Prices	133%	-20%	-34%	-29%	-16%	-21%	7%	-3%	-47%	101%			
Price Effects	40001	401	200/	4=0/	460/	300/	4201	4401	4861	44=-1			
- subtotal	128%	1%	-38%	-15%	-16%	-38%	12%	-11%	-47%	117%			

Table B6: Level and drivers of differences in estimated 2015 expenditure per capita in each country compared to the other nine comparator countries combined, antidepressants

the other fill	Mixed			,							
	financing		Universa	public fina	ncing		ι	Jniversal soci	iversal social insurance financing		
			New	panene mie							
	Canada	Australia	Zealand	Norway	Sweden	UK	France	Germany	Netherlands	Switzerland	
Domestic											
expenditure	\$24.8	\$9.2	\$2.9	\$4.7	\$7.5	\$11.4	\$8.4	\$9.2	\$4.6	\$23.6	
Comparator											
expenditure	\$9.4	\$11.3	\$11.3	\$11.3	\$11.3	\$11.1	\$11.9	\$11.8	\$11.5	\$10.8	
Total											
difference in											
expenditure											
per capita	163%	-19%	-74%	-58%	-33%	3%	-30%	-22%	-60%	118%	
Domestic											
days per											
capita	35	32	27	22	31	36	19	20	17	21	
Comparator											
days per											
capita	25	25	26	26	26	23	28	28	26	26	
Difference in											
volume of											
therapy	44%	24%	3%	-16%	21%	52%	-32%	-29%	-36%	-19%	
Difference in											
cost per day											
of therapy	119%	-43%	-77%	-42%	-54%	-49%	2%	6%	-24%	137%	
Difference in											
expenditure											
per capita											
resulting											
from											
differences											
in drivers of											
cost per day											
of therapy											
Broad mix of											
therapies	-1%	-1%	-2%	-2%	-1%	0%	2%	0%	-1%	-1%	
Narrow mix											
of therapies	53%	38%	-39%	-18%	-14%	-55%	6%	4%	-1%	19%	
Choice											
Effects -											
subtotal	52%	37%	-41%	-20%	-15%	-55%	9%	4%	-2%	19%	
Generic use	-4%	-3%	-19%	12%	-10%	5%	4%	-4%	-3%	31%	
Prices	71%	-77%	-18%	-33%	-29%	1%	-10%	7%	-19%	87%	
Price Effects											
- subtotal	67%	-80%	-36%	-22%	-39%	6%	-7%	3%	-22%	118%	